Sensitive Damage in Leprosy: A Longitudinal and Retrospective Study

  • Amanda Teixeira Labelle Castanheira
  • Sabrina Sampaio Bandeira
  • Alianne Violet Alves Chichester
  • Ana Luisa Mendes dos Reis
  • Carlos Victor da Silva Nascimento
  • Caroline da Silva Alves Palheta
  • Walter Refkalefsky Loureiro
  • Francisca Regina de Oliveira Carneiro
  • Carla Andrea Avelar Pires

Abstract

Background: The evaluation of leprosy patients requires a careful dermatological and neurological examination in order to monitor the possible damage to the peripheral nerves. This study focused on evaluate the sensitivity at the time of diagnosis and discharge of leprosy patients from Dermatology Department of the State University of the State of Pará.  


Methods and Findings: this is a longitudinal, retrospective and descriptive study based on medical records that presented neurological assessment and degree of physical disability of 30 patients assisted at a referral service between 2016 and 2019, applying descriptive statistical analysis. Concerning neural involvement, 88.89% of the patients with neural damage were male, 100% of patients in this group were multibacillary (p-value: 0.02), 42.8% were borderliners (p-value: 0.04), 88.8% had some type of leprosy reaction (p-value: 0.02) and 44.4% of the patients had a diagnosis of leprosy with more than one year of disease evolution; most patients with neural involvement (N = 16) had more than one nerve affected, with the right tibial nerve being the most affected (24.14%); It was noted that a considerable portion of multibacillary patients did not improve or worsened (75%), and the borderline form was the one with the worst prognosis, showing 50% of patients did not respond to treatment.


Conclusions: Most of the patients with neural damage were multibacillary, and borderliners, with many of those without presenting improvement, or showing worsening of clinical condition after multidrug therapy. Thus, it is highlighted the primary role of longitudinal assessment of those patients, in view of the possibility of chronification and sequel development.

References

1. Brasil. Ministério da Saúde. Secretaria de Vigilância em Saúde. Coordenação-Geral de Desenvolvimento da Epidemiologia em Serviços. Guia de Vigilancia em Saude. Volume único.3 edição. Brasilia: Brasil; 2019. pagina 294-296

2. World Health Organization (‎2019)‎. Global leprosy update, 2018: moving towards a leprosy-free world Weekly Epidemiological Record. (2019); 94 (‎35/36)‎, 389 - 411. World Health Organization.

3. Hanseníase – DATASUS – Indicadores epidemiológicos e operacionais de hanseníase, por ano diagnóstico – Municípios/UF/Regiões/ Brasil-2018. Brasil: Ministério da Saúde. Available from: http://tabnet.datasus.gov.br/cgi/sinannetbd/hanseniase/hansDB2018.html

4. Brasil. Ministério da Saúde. Situação epidemiológica e estratégias de prevenção, controle e eliminação das doenças tropicais negligenciadas no Brasil, 1995 a 2016. Brasilia, Distrito Federal, 2018: Carmelita Ribeiro Filha (Editora científica), p.8. Available from: http://portalarquivos2.saude.gov.br/images/pdf/2018/novembro/19/2018-032.pdf

5. Brasil. Ministério da saúde. Vigilância em Saúde: Dengue, Esquistossomose, Hanseníase, malaria, Tracoma e Tuberculose. Caderno de Atenção Básica. n. 21. 2 ed. rev. Brasília 2008: Secretaria de Atenção à Saúde.

6. lastoria JC, Abreu MAMM. Hanseníase: Diagnostico e Tratamento. Diagn Tratamento. 2012;17(4):173-9.


7. Palú FH, Cetolin SF. Perfil clinico epidemiológico dos pacientes com hanseníase no extremo-oeste catarinense, 2004 a 2014. Arq. Catarin Med. 2015 abr-jun; 44(2): 90-98.


8. Brasil. Ministério da Saúde. Secretaria de Vigilância em Saúde. Departamento de Vigilância das Doenças Transmissíveis. Guia prático sobre a hanseníase [recurso eletrônico] / Ministério da Saúde, Secretaria de Vigilância em Saúde, Departamento de Vigilância das Doenças Transmissíveis. – Brasília : Ministério da Saúde, 2017.

9. Basombrio, G. et al. Draft report of classification Committee. In: Congresso Internacional de Leprologia; 1953; Madrid: Associación Internacional de la Lepra; 1953. p. 75- 86.

10. Como reconhecer e tratar reações hansênicas. Secretaria do estado de saúde de Minas Gerais Superintendencia de atenção à saúde, diretoria de normalização e atenção a saúde, coordenadoria estadual de Dermatologia sanitária de Minas Gerais. Belo Horizonte, Minas gerais. 2005. Pagina 29-30

11. Santana EMF, Brito KKG, Antas EMVA, Nogueira JDA, Laedebal ODCP, Silva MA, et al. Original article. Rev Inst Med Trop São Paulo. 2018;60(21).

12. Souza CDF. Hanseníase e determinantes sociais da saúde: Uma abordagem a partir de métodos quantitativos- Bahia, 2001-2015. 2018. Tese (Doutorado em Saúde Pública)- Instituto Aggeu Magalhães, Fundação Oswaldo Cruz, Recife, 2018.

13. Silva JSR, Palmeira IP, Sá AMM, Nogueira LMV, Ferreira AMR. Variáveis clínicas associadas ao grau de incapacidade física na hanseníase. Rev Cuid. 2019; 10(1)

14. Pires CAA, Chaves EC, Salmen CF, Balieiro AB da R, Santos MBL, de Araújo Filho GG, Mesquita FM, Bandeira SS, Xavier MB. Análise do perfil clínico- epidemiológico da hanseníase no Pará e avaliação dos indicadores de saúde. REAS [Internet]. jul.2019;(27):e899. Available from: https://acervomais.com.br/index.php/saude/article/view/899

15. Save MP, Dighe AR, Natrajan M, et al. Association of viable Mycobacterium leprae with Type 1 reaction in leprosy. Lepr Rev 2016; 87: 78–92.

16. Kamath S, Vaccaro SA, Rea TH, Ochoa MT. reactions in leprosy. J Am Dermatology. 2014;71(4):795–803.

17. Reyila VP, Betsy A, Riyaz N, Sasidharanpillai S, Veil P. Clinico-epidemiological study of disability due to leprosy at the time of diagnosis among patients attending a tertiary care institution. Indian J Dermatol. 2019;64(2):106–11.

18. Saunderson P, Bizuneh E, Leekassa R. Neuropathic pain in people treated for multibacillary leprosy more than ten years previously. Lepr Rev. 2008;79(3):270–6

19. Lockwood DNJ. Chronic aspects of leprosy—neglected but important. Trans R Soc Trop Med Hyg. 2019;112(12):813–7.

20. Raposo MT, Reis MC, Caminha AVQ, Heukelbach J, Parker LA, Pastor-Valero M, et al. (2018) Grade 2 disabilities in leprosy patients from Brazil: Need for follow-up after completion of multidrug therapy. PLoS Negl Trop Dis 12(7): e0006645.

21. Santana EMF de, Brito KKG, Nogueira JDA, Leadebal ODCP, Costa MML, Silva MA da, et al. Deficiências e incapacidades na hanseníase: do diagnóstico à alta por cura. Rev Eletrônica Enferm. 2018;20:1–11.

22. Aarão TL de, Sousa JR De, Falcão ASC, Falcão LFM, Quaresma JAS. Nerve Growth Factor and Pathogenesis of Leprosy: Review and Update. 2018;9(May):1–8.
Published
2020-02-02
How to Cite
CASTANHEIRA, Amanda Teixeira Labelle et al. Sensitive Damage in Leprosy: A Longitudinal and Retrospective Study. International Archives of Medicine, [S.l.], v. 13, feb. 2020. ISSN 1755-7682. Available at: <http://imedicalpublisher.com/ojs/index.php/iam/article/view/2915>. Date accessed: 20 jan. 2021. doi: https://doi.org/10.3823/2618.
Section
Dermatology

Most read articles by the same author(s)